A nasal spray formulation of adrenaline, a needle-free alternative in the emergency treatment of anaphylaxis, has been ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab (Benlysta®) treatment for children ages five years and older with active ...

The FDA expanded the approval of the SONU Band to include the treatment of patients aged 12 years and older with moderate to severe nasal congestion due to allergic or nonallergic rhinitis ...

The US Food and Drug Administration has approved a new system for nerve repair based on light-activated polymers rather than surgical stitches. The flexible polymer system was developed by the ...

Utah biochemist Wesley Sundquist has achieved yet another milestone with the Food and Drug Administration approval of an antiviral drug for HIV prevention based on his findings.

The U.S. Food and Drug Administration has approved Andembry (garadacimab-gxii) as the only treatment targeting factor XIIa for prophylactic use to prevent attacks of hereditary angioedema (HAE).

Gilead's FDA-approved Yeztugo, a twice-yearly injectable HIV PrEP, showed near-perfect trial efficacy but faces backlash over its $28K annual price.

The FDA’s decision makes Dupixent (dupilumab), an interleukin-4 and -13 inhibitor, the first approved treatment indicated for bullous pemphigoid (BP) in the United States.

FDA approves new indication for Keytruda The approval introduces the first perioperative anti-PD-1 treatment regimen for adults with resectable locally advanced head and neck squamous cell carcinoma.

The FDA approved Gilead's HIV prevention drug lenacapavir, a twice-a-year injectable medication that clinical trials show prevents new infections.

The FDA has approved the first twice-yearly shot to reduce the risk of HIV infections.

Pharmaceutical company Gilead Sciences announced Wednesday the Food and Drug Administration (FDA) has approved its six-month, twice-yearly HIV PrEP injection, which was found in trials to be more t… ...